Former OpenAI science lead Kevin Weil has launched Warp Sciences to automate lab work for drug discovery, securing a 215 million dollar funding round.
TechCrunch reports that the newly established artificial intelligence startup aims to train robots to manufacture and test promising chemical compounds identified by researchers. Kevin Weil announced the launch and the financing on X, revealing that the company achieved an evaluation of 865 million dollars. The substantial funding round was led by Lightspeed, with additional financial participation from IVP, Premji Invest, and Lux Capital.
Biotechnology firms have historically relied on contractors in China, such as WuXi AppTec, to handle the labor intensive process of synthesizing thousands of molecular variations. Through Warp Sciences, the founder intends to bring this operational work back domestically. The strategy seeks to protect the pharmaceutical development pipeline from potential geopolitical supply chain vulnerabilities.
Background
The operational framework of the startup involves human chemists wearing cameras and sensor gloves to teach robots how to execute routine laboratory procedures. By deploying automated machinery capable of functioning continuously around the clock, the company intends to significantly speed up the pace of pharmaceutical research.
Why It Matters
The launch highlights a growing convergence between robotics and artificial intelligence within the life sciences sector. By attempting to localize laboratory automation, the company addresses longstanding supply chain concerns that affect pharmaceutical research. If successful, the approach could alter how molecular testing is scaled, shifting heavy reliance on overseas contractors toward automated domestic facilities.
Illustration: AI-generated image, not a photograph of the event.